Home › Jazz Pharmaceuticals And Gentium Announce European Commercial Launch Of First Approved Life-Saving Treatment For Severe Hepatic Veno-Occlusive Disease
 

Keywords :   


Jazz Pharmaceuticals And Gentium Announce European Commercial Launch Of First Approved Life-Saving Treatment For Severe Hepatic Veno-Occlusive Disease

2014-04-02 06:18:01| drugdiscoveryonline News Articles

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Gentium S.p.A., a Jazz Pharmaceuticals company, today announced the commencement of the European commercial launch of Defitelio® (defibrotide), the first licensed product for the treatment of severe hepatic veno-occlusive disease (severe VOD or sVOD) in patients over one month of age undergoing haematopoietic stem cell transplantation (HSCT) therapy

Tags: commercial treatment approved european

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
10.10Hurricane Milton Update Statement
10.10Summary for Hurricane Milton (AT4/AL142024)
10.10Hurricane Milton Public Advisory Number 19A
10.10Eastern North Pacific Tropical Weather Outlook
10.10Atlantic Tropical Weather Outlook
10.10Spain looks to immigrants to drive economy
10.10Reeves 'must find billions more' in time for Budget
10.10Government to outline major overhaul of workers' rights
More »